UT-MD Anderson Cancer Center: Sotorasib Shows Clinically Meaningful Activity In KRAS G12C-Mutated Advanced Pancreatic Cancer
December 22, 2022
December 22, 2022
HOUSTON, Texas, Dec. 22 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Dec. 21, 2022:
* * *
CodeBreaK 100 study demonstrates acceptable safety profile and encouraging results
* * *
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metasta . . .
* * *
CodeBreaK 100 study demonstrates acceptable safety profile and encouraging results
* * *
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metasta . . .